Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients

Erik Asmus; Weronika Karle; Markus C Brack; Corey Wittig; Felix Behrens; Leander Reinshagen; Moritz Pfeiffer; Sabrina Schulz; Bertina Mandzimba-Maloko; Lasti Erfinanda; Paul L Perret; Laura Michalick; Patrick J Smeele; Endry H T Lim; Charissa E van den Brom; Alexander B A Vonk; Toralf Kaiser; Norbert Suttorp; Stefan Hippenstiel; Leif E Sander; Florian Kurth; Ursula Rauch; Ulf Landmesser; Arash Haghikia; Robert Preissner; Harm J Bogaard; Martin Witzenrath; Wolfgang M Kuebler; Robert Szulcek; Szandor Simmons

doi:10.1183/13993003.02009-2022

Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients

Eur Respir J. 2023 Mar 23;61(3):2202009. doi: 10.1183/13993003.02009-2022. Print 2023 Mar.

Authors

Erik Asmus¹, Weronika Karle¹, Markus C Brack^{2

3}, Corey Wittig¹, Felix Behrens^{1

4}, Leander Reinshagen^{5

6}, Moritz Pfeiffer², Sabrina Schulz¹, Bertina Mandzimba-Maloko¹, Lasti Erfinanda¹, Paul L Perret^{1

4}, Laura Michalick^{1

5}, Patrick J Smeele⁷, Endry H T Lim^{8

9}, Charissa E van den Brom^{8

10}, Alexander B A Vonk¹¹, Toralf Kaiser¹², Norbert Suttorp^{2

13}, Stefan Hippenstiel^{2

13}, Leif E Sander^{2

13}, Florian Kurth^{2

13}, Ursula Rauch^{5

6}, Ulf Landmesser^{4

5

6}, Arash Haghikia^{4

5

6}, Robert Preissner^{1

14}, Harm J Bogaard⁷, Martin Witzenrath^{2

3

13}, Wolfgang M Kuebler^{1

5

13

15

16

17}, Robert Szulcek^{1

7

18

17}, Szandor Simmons^{19

5

17}

Affiliations

¹ Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
² Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
³ Division of Pulmonary Inflammation, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
⁴ Berlin Institute of Health (BIH), Berlin, Germany.
⁵ DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
⁶ Department of Cardiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
⁷ Department of Pulmonary Diseases, Amsterdam UMC, VU University Medical Center, Amsterdam Cardiovascular Sciences (ACS), Amsterdam, The Netherlands.
⁸ Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
⁹ Department of Neurology, University of Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam, The Netherlands.
¹⁰ Department of Anesthesiology, Amsterdam UMC, VU University Amsterdam, Amsterdam, The Netherlands.
¹¹ Department of Cardiothoracic Surgery, Amsterdam UMC, VU University Amsterdam, Amsterdam, The Netherlands.
¹² German Rheumatism Research Centre Berlin (DRFZ) - Flow Cytometry Core Facility, Berlin, Germany.
¹³ German Center for Lung Research (DZL), Partner site Berlin, Berlin, Germany.
¹⁴ Science-IT, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
¹⁵ The Keenan Research Centre for Biomedical Science at St. Michael's, Toronto, ON, Canada.
¹⁶ Departments of Surgery and Physiology, University of Toronto, Toronto, ON, Canada.
¹⁷ These authors contributed equally to this work.
¹⁸ German Heart Center Berlin, Berlin, Germany.
¹⁹ Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany szandor.simmons@charite.de.

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators reduce agonist-induced platelet activation and function. CFTR modulators, such as ivacaftor, present a promising therapeutic strategy in thrombocytopathies, including severe COVID-19. https://bit.ly/3HJykdt

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19*
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis*
Health Status
Humans
Mutation
Platelet Activation

Substances

Cystic Fibrosis Transmembrane Conductance Regulator